Abstract

Background: It remains unclear whether the 22- and 25-gauge needles have equal diagnostic yields in endoscopic ultrasonography–fine needle aspiration of pancreatic masses. Methods: Patients presenting with pancreatic solid masses were prospectively included between July 2010 and June 2012. Each patient underwent ultrasonography–fine needle aspiration using two different needle sizes (22- and 25-gauge needles) during the same endoscopic session, the 25 and 22 needle sequence being randomized. Cytological preparations included smear cytology, ThinPrep and Cell Block. Specimens were analyzed for diagnosis, cellularity, amount of blood and digestive contamination. Final diagnosis was reached by the final pathological report, clinical and radiological follow-up. Results: Thirty-seven patients were included among them 34 subjects had malignant pancreatic neoplasm on final diagnosis. Pancreatic masses were located in the head of pancreas in 73% of cases. The mean size of the lesions was 34.6 ± 14.4 mm. Diagnostic yields of the 25- and 22-gauge needles were 85.3% (95%CI: 72.6-98) and 88.2% (95%CI:76.7-99.7) respectively (p > 0.05). Diagnosis was obtained with smear cytology alone in 58.8% patients with the 22-gauge needle and in 55.9% patients with the 25-gauge needle, in 64.5% patients with Cell Block for both needles and in 76.5% with ThinPrep for both needles. The quality of specimens was comparable with the two needles. No complication occurred. Conclusion: The 25- and 22-gauge needles carry the same diagnostic yield when performing ultrasonography– fine needle aspiration of solid pancreatic masses. ISRCTN69545565 Controlled trials.

Highlights

  • Fine-needle aspiration guided by endoscopic ultrasonography (EUS-FNA) has changed the management of solid pancreatic masses

  • Thirty-seven patients were included among them 34 subjects had malignant pancreatic neoplasm on final diagnosis

  • Diagnosis was obtained with smear cytology alone in 58.8% patients with the 22-gauge needle and in 55.9% patients with the 25-gauge needle, in 64.5% patients with Cell Block for both needles and in 76.5% with ThinPrep for both needles

Read more

Summary

Introduction

Fine-needle aspiration guided by endoscopic ultrasonography (EUS-FNA) has changed the management of solid pancreatic masses. While EUS can provide supplementary information regarding the staging of pancreatic tumors, FNA can be safely performed on pancreatic masses and/or peripancreatic lymph nodes to bring the ultimate diagnosis of malignancy. Because the differential diagnosis of solid pancreatic masses is wide including benign, premalignant and malignant conditions, sampling the mass is of great interest before sending the patient to demanding and complicated surgery. Tumor sampling is currently recommended only when the pancreatic mass does not seem amenable to resection because of staging results or poor physical condition. A recent meta-analysis including almost 5’000 patients who underwent EUS-. It remains unclear whether the 22- and 25-gauge needles have equal diagnostic yields in endoscopic ultrasonography–fine needle aspiration of pancreatic masses

Objectives
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call